Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 10.07% is 12% above its 5-year average of 8.95%, around the middle of its 5-year range (5.97%–12.90%).
As of the fiscal period ended Tuesday, June 30, 2026. 1.62% below its 12-month average of 10.23%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 10.07%.
RETURN ON EQUITY (ROE)
10.07%
RETURN ON EQUITY (ROE) AVG TTM
10.23%
RETURN ON EQUITY (ROE) AVG 3Y
9.11%
RETURN ON EQUITY (ROE) AVG 5Y
8.95%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-1.62%
CURRENT VS 3Y AVG
+10.45%
CURRENT VS 5Y AVG
+12.47%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 753 covered companies
CURRENT VS SECTOR MEDIAN
+123.96%
vs the sector median at left
Viemed Healthcare, Inc.
Market Cap
$355.36M
Return on Equity (ROE)
10.07%
TTM Avg
10.23%
3Y Avg
9.11%
5Y Avg
8.95%
Market Cap
$355.43M
Return on Equity (ROE)
-26.14%
TTM Avg
-53.80%
3Y Avg
-12.25%
5Y Avg
19.21%
Market Cap
$353.88M
Return on Equity (ROE)
-62.56%
TTM Avg
-108.31%
3Y Avg
-79.06%
5Y Avg
-57.33%
Market Cap
$353.00M
Return on Equity (ROE)
N/A
TTM Avg
-12.63%
3Y Avg
-14.73%
5Y Avg
14.28%
Market Cap
$352.67M
Return on Equity (ROE)
N/A
TTM Avg
187.63%
3Y Avg
25.60%
5Y Avg
-9.96%
Market Cap
$359.53M
Return on Equity (ROE)
-7.66%
TTM Avg
-10.18%
3Y Avg
260.20%
5Y Avg
144.75%
Market Cap
$349.70M
Return on Equity (ROE)
-200.64%
TTM Avg
-134.16%
3Y Avg
-101.12%
5Y Avg
-54.69%
Market Cap
$361.64M
Return on Equity (ROE)
N/A
TTM Avg
-589.37%
3Y Avg
-290.01%
5Y Avg
-205.39%
Market Cap
$346.73M
Return on Equity (ROE)
-1229.58%
TTM Avg
464.26%
3Y Avg
-581.37%
5Y Avg
-581.37%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Viemed Healthcare, Inc. (VMD) | $355.36M | 10.07% | 10.23% | 9.11% | 8.95% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.43M | -26.14% | -53.80% | -12.25% | 19.21% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $353.88M | -62.56% | -108.31% | -79.06% | -57.33% |
| Embecta Corp. (EMBC)vs › | $353.00M | N/A | -12.63% | -14.73% | 14.28% |
| Ocugen, Inc. (OCGN)vs › | $352.67M | N/A | 187.63% | 25.60% | -9.96% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.53M | -7.66% | -10.18% | 260.20% | 144.75% |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $349.70M | -200.64% | -134.16% | -101.12% | -54.69% |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | N/A | -589.37% | -290.01% | -205.39% |
| Turn Therapeutics Inc. (TTRX)vs › | $346.73M | -1229.58% | 464.26% | -581.37% | -581.37% |
| Relmada Therapeutics, Inc. (RLMD)vs › | $344.04M | -29.98% | -145.74% | -129.76% | -105.96% |
ROE
10.1%
ROA
7.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 10.07% |
| 2026-03-31 | 10.35% |
| 2025-12-31 | 10.55% |
| 2025-09-30 | 10.19% |
| 2025-06-30 | 10.00% |
| 2025-03-31 | 9.12% |
| 2024-12-31 | 8.57% |
| 2024-09-30 | 8.34% |
| 2024-06-30 | 7.93% |
| 2024-03-31 | 8.88% |
| 2023-12-31 | 8.99% |
| 2023-09-30 | 8.46% |
| 2023-06-30 | 7.02% |
| 2023-03-31 | 5.97% |
| 2022-12-31 | 6.41% |
| 2022-09-30 | 8.38% |
| 2022-06-30 | 9.23% |
| 2022-03-31 | 9.58% |
| 2021-12-31 | 9.62% |
| 2021-09-30 | 11.31% |
| 2021-06-30 | 12.90% |
| 2021-03-31 | 34.73% |
| 2020-12-31 | 38.60% |
| 2020-09-30 | 38.36% |
| 2020-06-30 | 40.78% |
| 2020-03-31 | 23.39% |
| 2019-12-31 | 20.88% |
| 2019-09-30 | 22.45% |
| 2019-06-30 | 23.54% |
| 2019-03-31 | 26.80% |
| 2018-12-31 | 31.25% |
| 2018-09-30 | 21.68% |
| 2018-06-30 | 29.31% |
| 2018-03-31 | 30.42% |
| 2017-12-31 | 34.43% |
| 2017-09-30 | 53.08% |
